{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:15:54Z","timestamp":1772813754596,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[1996,10,1]],"date-time":"1996-10-01T00:00:00Z","timestamp":844128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":8500,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1996,10]]},"DOI":"10.1093\/oxfordjournals.annonc.a010757","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T21:50:41Z","timestamp":1334785841000},"page":"793-799","source":"Crossref","is-referenced-by-count":16,"title":["2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III\u2013IV non-Hodgkin's lymphoma"],"prefix":"10.1016","volume":"7","author":[{"given":"D.C.","family":"Betticher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"von Rohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Egger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Radford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ambrosetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"B\u00fcrki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Rufener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.F.","family":"Hsu Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0950-3536(87)80048-3","article-title":"Follicular non-Hodgkin's lymphoma","volume":"1","author":"Gallagher","year":"1987","journal-title":"Bailleres Clin Haematol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/oxfordjournals.annonc.a058157","article-title":"Therapy of relapsed or refractory low-grade follicular lymphomas: Factors associated with complete remission, survival and time to treatment failure","volume":"3","author":"Spinolo","year":"1992","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1093\/oxfordjournals.annonc.a010757_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199400476-00004","article-title":"The management of follicular lymphomas","volume":"47","author":"Rohatiner","year":"1994","journal-title":"Drugs"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0020","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center","volume":"13","author":"Johnson","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0025","series-title":"Non-Hodgkin's Lymphomas","first-page":"317","article-title":"Treatment of low-grade non-Hodgkin's lymphomas","author":"Gisselbrecht","year":"1993"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.1994.12.6.1177","article-title":"Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma","volume":"12","author":"Rohatiner","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.1994.12.8.1541","article-title":"Clinical significance of t(14;18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission","volume":"12","author":"Lambrechts","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0040","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0045","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1182\/blood.V83.12.3800.3800","article-title":"Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow","volume":"83","author":"Gribben","year":"1994","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0050","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.1994.12.4.798","article-title":"Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma","volume":"12","author":"Johnson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0055","first-page":"96","article-title":"New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas","volume":"20","author":"Cheson","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.annonc.a059209","article-title":"Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias","volume":"6","author":"Pott-Hoeck","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0065","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7326\/0003-4819-120-9-199405010-00010","article-title":"2-Chlorodeoxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies","volume":"120","author":"Saven","year":"1994","journal-title":"Ann Int Med"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/bjc.1993.24","article-title":"2\u2032-Chlorodeoxyadenosine: Evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies","volume":"67","author":"Hickish","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0075","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1992.10.3.371","article-title":"2-Chlorodeoxyadenosine treatment of low-grade lymphomas","volume":"10","author":"Kay","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","article-title":"2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma","volume":"12","author":"Hoffman","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oxfordjournals.annonc.a058693","article-title":"High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias","volume":"5","author":"Betticher","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0090","series-title":"Handbook for Reporting Results of Cancer Treatment","author":"World Health Organization","year":"1979"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0095","first-page":"89","article-title":"Prognostic factors in follicular lymphomas","volume":"20","author":"Coiffier","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0100","first-page":"191","article-title":"Intermittent infusion of cladribine (CdA) in previously treated low grade non-Hodgkin's lymphoma (LG-NHL): Response, toxicity and survival","volume":"14","author":"Liliemark","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0105","first-page":"386","article-title":"2-Chloro-2\u2032-deoxyadenosine (2-CDA), an active agent in the treatment of advanced relapsed or refractory low to intermediate grade non-Hodgkin's lymphoma","volume":"13","author":"Khan","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010757_bb0110","first-page":"56a","article-title":"2-CDA treatment of untreated low grade non-Hodgkin lymphomas \u2013 preliminary results of a phase II study","volume":"86","author":"Rummel","year":"1995","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0115","first-page":"425","article-title":"Long-term follow-up after 2-chlorodeoxyadenosine therapy in previously treated advanced non-Hodgkin's lymphoma (NHL)","volume":"15","author":"Kong","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010757_bb0120","first-page":"56a","article-title":"Response and toxicity of cladribine (2-CDA) as first line treatment of low-grade non-Hodgkin's lymphomas (NHL). Preliminary data of an Austrian multicentre trial","volume":"86","author":"Fridrik","year":"1995","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010757_bb0125","first-page":"274a","article-title":"Bolus infusion 2-chlorodeoxyadenosine (2-CDA) as first-line therapy of low grade non-Hodgkin's lymphoma (NHL): CALGB 9153","volume":"86","author":"Piro","year":"1995","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0130","first-page":"410","article-title":"Response and toxicity of cladribine (2-CDA) as first line treatment of low grade non-Hodgkin's lymphomas (NHL). Preliminary data of an Austrian multicenter trial","volume":"15","author":"J\u00e4ger","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0135","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V86.5.1710.bloodjournal8651710","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin's lymphoma","volume":"86","author":"Saven","year":"1995","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.1996.14.2.514","article-title":"Phase II trial of fludarabine monophosphate as a first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the groupe d'\u00e9tude des lymphomes de l'adulte","volume":"14","author":"Solal-C\u00e9ligny","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood.V76.1.131.131","article-title":"Direct sequence analysis of the 14q+ and 18q- chromosome junctions in follicular lymphoma","volume":"76","author":"Cotter","year":"1990","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0150","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/bjc.1993.171","article-title":"Detection of bcl-2\/JH rearrangement in follicular and diffuse lymphoma: Concordant results of peripheral blood and bone marrow analysis at diagnosis","volume":"67","author":"Yuan","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.1995.tb08938.x","article-title":"Detection of t(14;18) in British follicular lymphoma using cytogenetics, Southern blotting and the polymerase chain reaction","volume":"89","author":"Turner","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0160","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.1991.9.9.1527","article-title":"The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma","volume":"9","author":"Price","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0165","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","article-title":"All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment","volume":"78","author":"Gribben","year":"1991","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a058511","article-title":"Immunosuppression with purine analogues \u2013 the flip side of the gold coin","volume":"4","author":"Keating","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0175","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","article-title":"Antileukemic and immunosuppressive activity of 2-chloro-2-deoxyadenosine","volume":"81","author":"Carson","year":"1984","journal-title":"Proc Natl Acad Sci"},{"key":"10.1093\/oxfordjournals.annonc.a010757_bb0180","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419615735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419615735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/7\/8\/793\/474083\/7-8-793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T01:25:02Z","timestamp":1582248302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419615735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,10]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[1996,10]]}},"alternative-id":["S0923753419615735"],"URL":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010757","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1996,10]]}}}